S
Serge Muyldermans
Researcher at Vrije Universiteit Brussel
Publications - 323
Citations - 30516
Serge Muyldermans is an academic researcher from Vrije Universiteit Brussel. The author has contributed to research in topics: Single-domain antibody & Antibody. The author has an hindex of 80, co-authored 305 publications receiving 26561 citations. Previous affiliations of Serge Muyldermans include Dalian University of Technology & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
Yana Dekempeneer,Marleen Keyaerts,Ahmet Krasniqi,Janik Puttemans,Serge Muyldermans,Tony Lahoutte,Matthias D'Huyvetter,Nick Devoogdt +7 more
TL;DR: It is argued that the nanobodies’ pharmacokinetic properties match perfectly with the interesting decay properties of the short-lived α-particle emitting radionuclides Astatine-211 and Bismuth-213 and offer an interesting treatment option particularly for micrometastatic cancer and residual disease.
Journal ArticleDOI
Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice.
Lea Olive Tchouate Gainkam,Vicky Caveliers,Nick Devoogdt,Christian Vanhove,Catarina Xavier,Otto C. Boerman,Serge Muyldermans,Axel Bossuyt,Tony Lahoutte +8 more
TL;DR: Megalin contributes to the renal accumulation of (99m)Tc-7C12 and the combined effect of gelofusine and lysine was the most effective, namely a reduction of renal retention and improved tumor uptake.
Journal ArticleDOI
In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT
Ilse Vaneycken,Jochen Govaert,Cécile Vincke,Vicky Caveliers,Tony Lahoutte,Patrick De Baetselier,Geert Raes,Axel Bossuyt,Serge Muyldermans,Nick Devoogdt +9 more
TL;DR: This study shows the potency of antigen-binding loop-grafting to efficiently generate humanized Nanobodies that retain their targeting capacities for noninvasive in vivo imaging of tumors.
Journal ArticleDOI
A bispecific nanobody to provide full protection against lethal scorpion envenoming
Issam Hmila,Dirk Saerens,Rahma Ben Abderrazek,Cécile Vincke,Naima Abidi,Zakaria Benlasfar,Jochen Govaert,Mohamed El Ayeb,Balkiss Bouhaouala-Zahar,Balkiss Bouhaouala-Zahar,Serge Muyldermans +10 more
TL;DR: To ameliorate the current 100‐kDa horse plasma antivenom serum (PAS)‐derived Fab′2 to more quickly reach the highly diffusible scorpion toxins, the designed bispecific NbF12‐10 against AahI′/AahII toxins succeeded in neutralizing 5 LD50.
Journal ArticleDOI
Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations.
Mireille Dumoulin,Denis Canet,Els Pardon,David B. Archer,Serge Muyldermans,Lode Wyns,André Matagne,Carol V. Robinson,Christina Redfield,Christopher M. Dobson +9 more
TL;DR: Results indicate that the reduction in global cooperativity, and the associated ability to populate transiently a specific, partly unfolded intermediate state under physiologically relevant conditions, is a common feature underlying the behaviour of these two pathogenic mutations.